184 related articles for article (PubMed ID: 16712905)
1. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
Fracasso PM; Blessing JA; Molpus KL; Adler LM; Sorosky JI; Rose PG
Gynecol Oncol; 2006 Nov; 103(2):523-6. PubMed ID: 16712905
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.
Fracasso PM; Blessing JA; Morgan MA; Sood AK; Hoffman JS
J Clin Oncol; 2003 Aug; 21(15):2856-9. PubMed ID: 12885801
[TBL] [Abstract][Full Text] [Related]
3. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study.
Grendys EC; Blessing JA; Burger R; Hoffman J
Gynecol Oncol; 2005 Aug; 98(2):249-53. PubMed ID: 15978659
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.
Oki Y; McLaughlin P; Pro B; Hagemeister FB; Bleyer A; Loyer E; Younes A
Cancer; 2005 Aug; 104(4):781-7. PubMed ID: 15973667
[TBL] [Abstract][Full Text] [Related]
5. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.
Wadler S; Levy DE; Lincoln ST; Soori GS; Schink JC; Goldberg G
J Clin Oncol; 2003 Jun; 21(11):2110-4. PubMed ID: 12775736
[TBL] [Abstract][Full Text] [Related]
6. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
Miller DS; Blessing JA; Drake RD; Higgins R; McMeekin DS; Puneky LV; Krasner CN
Gynecol Oncol; 2009 Dec; 115(3):443-6. PubMed ID: 19804902
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Plaxe SC; Blessing JA; Husseinzadeh N; Webster KD; Rader JS; Dunton CJ
Gynecol Oncol; 2002 Feb; 84(2):241-4. PubMed ID: 11812081
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Hoffman MA; Blessing JA; Nuñez ER
Gynecol Oncol; 2001 Jun; 81(3):433-5. PubMed ID: 11371134
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
[TBL] [Abstract][Full Text] [Related]
10. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.
Garcia AA; Blessing JA; Nolte S; Mannel RS;
Gynecol Oncol; 2008 Oct; 111(1):22-6. PubMed ID: 18675446
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
[TBL] [Abstract][Full Text] [Related]
12. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group.
Moore DH; Blessing JA; Dunton C; Buller RE; Reid GC
Gynecol Oncol; 1999 Dec; 75(3):473-5. PubMed ID: 10600310
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
Hoffman MA; Blessing JA; Morgan M
Gynecol Oncol; 2000 Dec; 79(3):463-5. PubMed ID: 11104620
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
[TBL] [Abstract][Full Text] [Related]
15. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
[TBL] [Abstract][Full Text] [Related]
17. A Phase II study of oxaliplatin in urothelial cancer.
Winquist E; Vokes E; Moore MJ; Schumm LP; Hoving K; Stadler WM
Urol Oncol; 2005; 23(3):150-4. PubMed ID: 15907713
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
Plaxe SC; Blessing JA; Bookman MA; Creasman WT
Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Miller DS; Blessing JA; Waggoner S; Schilder J; Sorosky J; Bloss J; Schilder R
Gynecol Oncol; 2005 Jan; 96(1):67-71. PubMed ID: 15589582
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
